Compare NEXA & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEXA | PVLA |
|---|---|---|
| Founded | 1956 | 2015 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2017 | 2013 |
| Metric | NEXA | PVLA |
|---|---|---|
| Price | $13.25 | $150.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | $10.40 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 770.8K | 158.2K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | N/A | ★ 52.62 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,810,000.00 |
| Revenue This Year | $8.69 | N/A |
| Revenue Next Year | N/A | $104,350.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.28 |
| 52 Week Low | $4.82 | $53.30 |
| 52 Week High | $16.89 | $161.38 |
| Indicator | NEXA | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 50.00 |
| Support Level | $11.43 | $135.68 |
| Resistance Level | $15.03 | $158.29 |
| Average True Range (ATR) | 0.76 | 6.90 |
| MACD | -0.11 | -0.31 |
| Stochastic Oscillator | 4.21 | 63.65 |
Nexa Resources SA operate large-scale, mechanized underground and open pit mines, as well as smelters. The company operates through two segments namely Mining and Smelting. Its Mining segment consists of various operating units includes mineral exploration activities and the production of zinc concentrates, copper concentrates and concentrates. The Smelting segment comprises operating units which include facilities recovering and refining zinc metal out of feed materials such as zinc concentrates or secondary feed materials. It generates maximum revenue from the Smelting segment. Geographically It has a presence in Brazil, Peru, the United States of America, Switzerland, Japan, Argentina, South Korea, Colombia, Vietnam, Malaysia and other countries.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.